Skip to main content
Premium Trial:

Request an Annual Quote

SDIX's Q4 Revenues, Loss Decline

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SDIX, the firm previously known as Strategic Diagnostics, reported after the close of the market Thursday that its fourth-quarter revenues fell 11 percent, but the firm managed to cut its loss to almost zero for the quarter.

The Newark, Del.-based firm generated total revenues of $6.2 million for the three-month period ended Dec. 31, compared to $7 million for the fourth quarter of 2008. It said that its life sciences sales were down 21 percent $3 million for the quarter, down from $3.8 million year over year, while kit sales were up 7 percent to $3.2 million from $3 million.

The firm makes kits for a variety of testing applications including food pathogens, water and environment, and Ag-GMO.

SDIX's net loss was $65,000, or $0.00 per share, compared to a loss of $12.5 million, or $.62 per share, for the comparable period of 2008. The firm cut its expenses and also took a goodwill impairment charge of $4.2 million in the fourth quarter of 2008.

The firm's R&D expenses declined to $659,000 from $746,000 year over year, while its SG&A spending dropped to $2.7 million from $3.6 million.

For full-year 2009, SDIX had revenues of $27.2 million, down slightly from $27.7 million.

Its net loss dropped sharply to $1.7 million, or $.08 per share, from $15.8 million, or $.78 per share, year over year. A combination of lower spending, the prior year's impairment charge, and the elimination of an $8 million tax expense from the year before were the drivers of the lower loss.

SDIX's R&D spending fell to $2.9 million from $3.6 million, while its SG&A spending declined to $13.6 million from $14.4 million.

The firm finished the year with $9.2 million in available and restricted cash.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.